Bleomycin Sulfate

Catalog No.S1214 Synonyms: NSC125066

Bleomycin Sulfate Chemical Structure

Molecular Weight(MW): 1512.62

Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

Size Price Stock Quantity  
USD 170 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
In vitro

UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin sulfate with IC50 of 14.2 nM and 13 nM, respectively. [1] Alveolar macrophages incubated with 0.01 μg/mL to 1μg /mL Bleomycin sulfate for 18 hours secretes significantly more fibroblast growth factor than macrophages incubated without Bleomycin sulfate. Macrophages stimulated with Bleomycin sulfate continues to produce significant amounts of fibroblast growth factor even after Bleomycin sulfate is removed and replaced with fresh (Bleomycin sulfate-free) media. Fibroblast growth factor secretion by Bleomycin sulfate-stimulated alveolar macrophages is inhibited by cycloheximide, and the 5-lipoxygenase inhibitors NDGA (nordihydroguaiaretic acid) and BW755c, indicating not only a requirement for protein synthesis but also for metabolites of the 5-lipoxygenase pathway of arachidonic acid metabolism for full expression of activity. [2] Bleomycin sulfate (400 µg/mL) incubation for 24 hours decreases the viability of NTera-2 cells, and increases caspase-3, -8 and -9 activities, Bax and cytoplasmic cytochrome c levels and decreases Bcl-2 levels. [3] In terms of unstable aberrations, the clastogenic effect of Bleomycin sulfate on ADIPO-P2 cells persists for at least 10 days after exposure. Bleomycin sulfate-induced telomere instability in mammalian cells persists for several generations after exposure. Moreover, the appearance of telomere fusions in Bleomycin sulfate-exposed cells 10 days after treatment suggests that Bleomycin sulfate can induce delayed telomere instability. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
F98 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\aOFDjiJNzMECwJO69dQ>? NF3LdGQzPCCqwrC= NGTqPG1qdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NIW1XGkzPjB6OEexNS=>
POLK WT NYHTR|VUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TLbGlEPTB;MUGuO-KBkcLz4pEJNU44yqEQvF2= M{PzV|I3ODNzNECw
POLK KO NUj3O|d1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTRwMERihKnDueLCiUGuPVLDqM7:TR?= NWXFd4RIOjZyM{G0NFA>
POLK CD NX\0WZJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlv0TWM2OD13LkW55qCKyrIkgJmxMlAxyqEQvF2= NIO0bY8zPjB|MUSwNC=>
RLE/Abca3 NGXnVVRHfW6ldHnvckBCe3OjeR?= MWGwMlTDqM7:TR?= M17Zd|E1PMLiaB?= NUDsd4ljcW6mdXPld{BiKG2xcoDoc4xw\2mlYXygZ4hidmenIH\yc40h\XCrdHjlcIlidC2uaXvlJI1wenCqb3zv[5khfG9iYTD3bYRmNCC|cILlZYQud3W2IH3vdpBpd2yxZ4pCpC=> NIDycZQzPTd4MEWzPC=>
PMCs M3rFVWZ2dmO2aX;uJGF{e2G7 M3TDfVAvOeLCk{NCpO69\y:vbB?= NFzQXY0zPMLiaB?= MmfGZ4F2e2W|IHGg[I9{\S2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKHC{b4TlbY4hdGW4ZXygc4Yh[2:ubHHn[Y4uUcLi MXKyOVU6PTZ2Mh?=
PMCs NWPpXW5rTnWwY4Tpc44hSXO|YYm= NVe1TYxpOC5{wrFOwIcwdWx? NIrtRYEzPOLCk{eyxsBp MYfpcoR2[2W|IHnuZ5Jm[XOnczDpckB3cW2nboTpckBidmRizsGtV21CKHC{b4TlbY4> MVOyOVU6PTZ2Mh?=
PMCs MkC0SpVv[3Srb36gRZN{[Xl? MmHDNE4zyqEQvHevcYw> Ml7HO|IhcA>? NWPWPFRPcW6mdXPld{Bl\WO{ZXHz[ZMhcW5iY4n0c4tmemG2aX6tPEBidmRiRT3jZYRp\XKrbjDwdo91\Wmw Mlu2NlU2QTV4NEK=
PMCs M3HJdmZ2dmO2aX;uJGF{e2G7 MYewMlLDqM7:Zz;tcC=> NIThdHUyOi9{ND:0PEBp NF\RdodqdmO{ZXHz[ZMh[2WubDDtbYdz[XSrb36= M2r5N|I2PTl3NkSy
IMR-32 NF3TcYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrFO{426ojUMUKwJOK2\y:vbB?= NGjCT5EyOuLKkkS4JIg> MUnJR|UxRTZyINM1[{9udCCjdDD0bIUh\W6mIH;mJFI1KGi{czDv[kBqdmO3YnH0bY9v M1TXeVI2PTN4M{S1
HT1080 M1nyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTWVFlQOSEQvF2= MX2yOEBpyqB? M2\yOYxm[WS|IITvJIEhTzJxTTDk[YxigQ>? NV;z[JhjOjV3MUi5OlE>
HT1080 NXv3c4s5TnWwY4Tpc44hSXO|YYm= MmXtNUDPxE1? MV:yOEBpyqB? MVjpcoR2[2W|IHGgdI91\W62IHfsc4JidCCGTlGg[IFu[WenIILld5BwdnOn MYOyOVUyQDl4MR?=
HDFn MVTDfZRwfG:6aXPpeJkhSXO|YYm= M1K3bFczKGh? MmnZTWM2OD17LkOxKeKh NH61d5kzPTJ5Nke5Ni=>
THP-1 NYTGfGg1S3m2b4TvfIlkcXS7IFHzd4F6 NELxcHo4OiCq MlmzTWM2OD12Lke3KS=> M{XTT|I2Ojd4N{my
HT-29 MlrCR5l1d3SxeHnjbZR6KEG|c3H5 NVnDbWszPzJiaB?= MYDJR|UxRTFzLkS5KS=> MlXINlUzPzZ5OUK=
HCT116  NX\ifI55S3m2b4TvfIlkcXS7IFHzd4F6 MXO3NkBp M1joV2lEPTB;MUGuN|Qm NVfWRWx3OjV{N{[3PVI>
A431 NEjzXXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjz[lJuPTBvMkCwJGlW M1TyNVQ56oDLaB?= MonrbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NHThUHQzPTFyMUK5PS=>
T24 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7iOVAuOjByIFnV MmC2OFjjiImq MkHobY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M3\QOFI2OTBzMkm5
AY-27  M1;Tb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXTOVAuOjByIFnV NX3DOZRqPDkkgJno M4nYVolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NUC0OGhkOjVzMEGyPVk>
A549 MnjXSpVv[3Srb36gRZN{[Xl? NGj2NZgyKML3Zz;tUOKh NH\pXWUxNTR6IHi= MnzTbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mxsBQWE8EoH3SUmE> MUOyOFk3OzZ|NR?=
MLE12 NYLPWHdtTnWwY4Tpc44hSXO|YYm= NGmwVVUyKML3Zz;tUOKh M1vsSVAuPDhiaB?= NHTFWGxqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4bDqE:STtMgcXJPSQ>? M1[wW|I1QTZ|NkO1
Jurkat MnLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHaflVxOjEkgJpOwI0> MY[yOQKBkWkEoB?= M{THcYFzemW|dIOgeIhmKGOnbHygZ5lkdGViYYSgeIhmKEd{IIDoZZNm MXKyOFkyPjh7Mx?=
HeLa  NG\TTYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrENlFKSzVyPUGwMlLDqM7:TR?= M3q3fFI1PzN{M{m3
C18-4 NED3S5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjKTngxNTFyMDFOwG0> MXvpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MWWyOFU4OTl6Mh?=
BMG-1  MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWG0NE85OMLizsznM40> MkDSN:KhcA>? MXrpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MmD5NlM6ODZ5Mk[=
A459 NEnPUJhCeG:ydH;zbZMhSXO|YYm= MWqxNEBuXQ>? M4qzR|Q5KGh? NXG2O4lRcW6mdXPld{BieG:ydH;zbZM> NHX4NZczOzlyMke2Oi=>
MOCK MYLBdI9xfG:|aYOgRZN{[Xl? NGe4TFgyOCCvVR?= MW[0PEBp MXTpcoR2[2W|IHHwc5B1d3Orcx?= NUna[VVVOjN7MEK3OlY>
MMP1 NX\LWndISXCxcITvd4l{KEG|c3H5 MlPJNVAhdVV? MU[0PEBp MorVbY5lfWOnczDhdI9xfG:|aYO= NFvaV5AzOzlyMke2Oi=>
A549 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;mNlAxKM7:TR?= M{XldFI1KGkEoB?= NV[zZ4ZE\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? M1TOOVI{QDB3N{mz
HCT-116 NUK0dZV5SXCxcITvd4l{KEG|c3H5 M2PRWVMwPy53L{G1JO69\y:vbB?= MVO0PEBp NF3xNZNz\WS3Y3XzJJRp\SCuZY\lcEBw\iCETFigZZQhcGmpaDDjc45k\W62cnH0bY9v NGTHNWIzOzdyOE[2PC=>
HeLa M17JVGFxd3C2b4Ppd{BCe3OjeR?= MoPYN{84NjVxMUWg{txoN22u NYrZdYpLPDhiaB?= NEjJXnVz\WS3Y3XzJJRp\SCuZY\lcEBw\iCETFigZZQhcGmpaDDjc45k\W62cnH0bY9v MoPINlM4ODh4Nki=
HCT116 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rBbFAuOTByIN88[{9udA>? M2DBelQ5KGh? NYrGPJJDcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? Mkf3NlM2OTh{MEG=
NCM460 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFP6flYxNTFyMDFOwIcwdWx? NXnET2tZPDhiaB?= M{C3cYlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NVzLfZVyOjN3MUiyNFE>
NT2  NHL5SINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;qOFRvOjRiaNMg NUflVlg3VER3ME20NFDjiIoEtXevcYw> NX:weItlOjN|OE[0NlA>
NT2  NWDTUGZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDkVlJFPDhiaB?= NEfybWdNTDVyPUGwNEDDvWdxbXy= NWnod2ltOjN|OE[0NlA>
NT2  MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jVR|czKGh? M1HIeWxFPTB;MkFihKnDvWdxbXy= NXfq[mRyOjN|OE[0NlA>
NT2  Mn\pRZBweHSxc3nzJGF{e2G7 M3;wfVQxOOLCidM1[{9udA>? NGXodHczPCCqwrC= NXfMR3NvcW6mdXPld{B{cWewaX\pZ4FvfCCrbnPy[YF{\XNiaX6gZ4F{eGG|ZT2zMFgtQSCjY4Tpeol1gcLi M3L6UVI{Ozh4NEKw
NTera-2 NWPiUlJCTnWwY4Tpc44hSXO|YYm= MVmxNlAh|rypL33s M4fOOVczKGh? M4S2UpNq\26rZnnjZY51dHliaX7jdoVie2W|IEitbZNweHKxc4ThcoUhdGW4ZXzz NGm4bYYzOjh{NUO1OS=>
NCCIT MYfGeY5kfGmxbjDBd5NigQ>? NUDYfJdnOTJyIN88[{9udA>? Mn3yO|IhcA>? MUDzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyB6LXnzc5Bzd3O2YX7lJIxmfmWucx?= MYiyNlgzPTN3NR?=
NTera-2 Ml\ZSpVv[3Srb36gRZN{[Xl? NInxWWUyOjBizsznM41t NYPsSYJPPzJiaB?= NWfJeY96e2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgWGJCWlNibHX2[Yx{ MViyNlgzPTN3NR?=
NCCIT M1X0[mZ2dmO2aX;uJGF{e2G7 NVXJNI0xOTJyIN88[{9udA>? M2PjOlczKGh? M1HqcZNq\26rZnnjZY51dHliaX7jdoVie2W|IGTCRXJUKGyndnXsdy=> MV2yNlgzPTN3NR?=
NCCIT NGDvPGZHfW6ldHnvckBCe3OjeR?= MlLVNVIxKM7:Zz;tcC=> M4DCclczKGh? MmHNd4lodmmoaXPhcpRtgSCmZXPy[YF{\XNiR2PIJIxmfmWucx?= M1rqXVIzQDJ3M{W1
NTera-2 MnnMSpVv[3Srb36gRZN{[Xl? MmLVNVIxKM7:Zz;tcC=> MVy3NkBp M1LENZNq\26rZnnjZY51dHliaX7jdoVie2W|IGDyc5RmcW5iY3HyZo9vgWxibHX2[Yx{ MXiyNlgzPTN3NR?=
NCCIT MVvGeY5kfGmxbjDBd5NigQ>? NU\6WHFpOTJyIN88[{9udA>? M4TyS|czKGh? MXrzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCScn;0[YlvKGOjcnLvcpltKGyndnXsdy=> NEnYcmYzOjh{NUO1OS=>
NTera-2 M4nFVWZ2dmO2aX;uJGF{e2G7 MV[xNlAh|rypL33s NGXLWWs4OiCq M{noOJNq\26rZnnjZY51dHliaX7jdoVie2W|IFzQU{Bt\X[nbIO= NEXWfmQzOjh{NUO1OS=>
NCCIT M1jkPWZ2dmO2aX;uJGF{e2G7 NIXGT40yOjBizsznM41t NHLN[nM4OiCq NVjvXGFFe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgUHBQKGyndnXsdy=> NIH0OGgzOjh{NUO1OS=>
MDA-MB-468 NUKw[Y9vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PEVlDjiJN{MEFCpO69\y:vTB?= NWi5UFc4OjRiaB?= MkX5bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NETRN5YzOjhzOUG5Oi=>
231-H2N M1nLXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYGw5qCUOjBywrFOwIcwdUx? MWiyOEBp NEfxRlNqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MV2yNlgyQTF7Nh?=
A549  NH\XbXJHfW6ldHnvckBCe3OjeR?= NVfVc3p4OjByL{SwNEDPxE1? MkThdoV{fWy2czDpckBiKGSxc3WtdoV{eG:wc3n2[UBqdmO{ZXHz[UBqdiCUT2O= M1HFR|IzPzd|Nkm3
A549  M{\L[GZ2dmO2aX;uJGF{e2G7 NI\QTYIxNTRyMDFOwG0> NGHx[mIzNTR6IHi= M4PzXoNifXOnczDtc5JmKG22RF7BJJRp[W5iblTORUBl[W2jZ3W= MkD4NlI4PzN4OUe=
A549  MkTISpVv[3Srb36gRZN{[Xl? NGW3bVIyODBizszNxsA> NVHMVIJjOOLCk{S4JIg> NVPIVII{[2G3c3XzJINie3Cjc3WtN{Bi[3SrdnH0bY9v MWOyNlc4OzZ7Nx?=
A549  MUHGeY5kfGmxbjDBd5NigQ>? M1PFU|ExOCEQvF5CpC=> M2nHVFDjiJN2ODDo M4j4eYNifXOnczDQT2QyKGOuZXH2ZYdm NIe0SFczOjd5M{[5Oy=>
A549  NH\kTIdHfW6ldHnvckBCe3OjeR?= MUCxNFAh|ryPwrC= MYKw5qCUPDhiaB?= M1jyO4NifXOnczDtbZRw[2ixbnTybYFtKGyxY3HsbZpifGmxbjDv[kBD[Xh? NGK4bGIzOjd5M{[5Oy=>
A549  M1LBUWZ2dmO2aX;uJGF{e2G7 NWLrPW9oOTByIN88UeKh M3LqdVDjiJN2ODDo NI\VTGxl\WO{ZXHz[ZMhVU2SIHHu[EBCXFBibHX2[Yx{ MVqyNlc4OzZ7Nx?=
MCF-7/Her-18  MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUL2PZU6OC52Mj2xO|AxKM7:Zz;tUC=> MY[yOEBp MkPYbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> Mmm3NlI3OjF2MES=
MCF-7 NWLHOHdRWESWL2DDTUBVemWjdH3lcpQ> MXqwMlI2KM7:Zz;tcE4> NFe5R3oyNTRiaB?= NULRcmxHe2ixd4Ogd4lodmmoaXPhcpQhMFEEoEygNE4xPSliY4n0c5RwgGmlIHXm[oVkfA>? NEnwOpAzOjV7MUK4OC=>
MDA-MB-231 M1uwVHBFXC:SQ1mgWJJm[XSvZX70 MYmwMlI2KM7:Zz;tcE4> Mk[1NU01KGh? NGDwU|Z{cG:5czDzbYdvcW[rY3HueEApWMLiPDCwMlA2MSCleYTveI95cWNiZX\m[YN1 MYSyNlU6OTJ6NB?=
MDA-MB-235  NV\rd5lHWESWL2DDTUBVemWjdH3lcpQ> M2nsZlAvOjVizsznM41tNg>? MUixMVQhcA>? NHz4dWl{cG:5czDzbYdvcW[rY3HueEApWMLiPDCwMlA2MSCleYTveI95cWNiZX\m[YN1 Mor4NlI2QTF{OES=
MCF-7 MmjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvBWGwxNTJizsznM41tNg>? M2fwT|I1NzR6IHi= MkXtSWM2OD1zLkKg{txoN22O NXfneY5wOjJ3OUGyPFQ>
NCCIT  M4njTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITEPFkzOOLCk{G0NOKh|rypL33s M4LXTFczKGh? NV3zSFVlVER3ME2xNlDDqM7:Zz;tcOKh NH;xVoYzOjV4MkG2NC=>
NCCIT  M2fnUWZ2dmO2aX;uJGF{e2G7 MW[3NkBp NYG3dYp3e2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgZ4F{eGG|ZT2zJIFkfGm4aYT5xsA> MnrUNlI2PjJzNkC=
NCCIT  Ml7USpVv[3Srb36gRZN{[Xl? M4nOS|czKGh? NHjIc5Z{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDjZZNx[XOnLUigZYN1cX[rdIpCpC=> MYiyNlU3OjF4MB?=
NCCIT  NHHqSoNHfW6ldHnvckBCe3OjeR?= NF2xbYU4OiCq MoTWd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiY3HzdIF{\S17IHHjeIl3cXS7wrC= Mof3NlI2PjJzNkC=
NCCIT  M2rSXWZ2dmO2aX;uJGF{e2G7 NXvGTIFLPzJiaB?= M{LWV5Nq\26rZnnjZY51dHliaX7jdoVie2W|IFLBXEBt\X[nbB?= MonSNlI2PjJzNkC=
NCCIT  M4DoSmZ2dmO2aX;uJGF{e2G7 MkfkO|IhcA>? Mne1d4lodmmoaXPhcpRtgSCmZXPy[YF{\XNidHjlJGJkdC1{IHPvcpRmdnR? NF\YU|AzOjV4MkG2NC=>
NCCIT  NXHHS4VmTnWwY4Tpc44hSXO|YYm= MmX2O|IhcA>? NYjJd2tue2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgeIhmKEO7dD3jJIxmfmWu M{\WZVIzPTZ{MU[w
HeLa NGDFdY9HfW6ldHnvckBCe3OjeR?= NXm5bppFOzBxN{Cg{txoN22u MnvyNlTDqGh? NYPzeohucW6lcnXhd4V{KHSqZTDtVm5CKGyndnXsd{Bw\sLicEWz89yNSVSPLICyNeKh[W6mwrDHRWRFPDV? MWKyNlQ5Pzl|Nx?=
MCF-7  M{T5TGZ2dmO2aX;uJGF{e2G7 MlrSN|AwPzBizsznM41t MkLUNlTDqGh? M3z6TIlv[3KnYYPld{B1cGVibWLORUBt\X[nbIOgc4bDqHB3M,-8kGFVVSyyMkJCpIFv\MLiR1HESFQ2 MonsNlI1QDd7M{e=
HeLa NHrjXFFEgXSxdH;4bYNqfHliQYPzZZk> NWO4Z2F4OzBxN{Cg{txoN22u NXr3TZpvOjUEoHi= NUfIfndtcW6mdXPld{BpcWeqbImgd4lodmmoaXPhcpQhdGW4ZXzzJI9nKG[{YXft[Y51\WRiRF7BJJJmdGWjc3WgbY51dyC2aHWgZ5l1d3CuYYPt MoDGNlI1QDd7M{e=
MCF-7  NIq0e3pEgXSxdH;4bYNqfHliQYPzZZk> NIHtSXI{OC95MDFOwIcwdWx? NFrmTmszPMLiaB?= NYjVSGdGcW6mdXPld{BpcWeqbImgd4lodmmoaXPhcpQhdGW4ZXzzJI9nKG[{YXft[Y51\WRiRF7BJJJmdGWjc3WgbY51dyC2aHWgZ5l1d3CuYYPt NEXuVFkzOjR6N{mzOy=>
NT2 M33NNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETYOnMyODBvNkCwxsDPxGdxbXy= MlvFNlQhcA>? MV\JR|UxRTRyMDFCuYcwdWx? NY\Rb2RuOjJ2Nkm5OVI>
NT2 MXzGeY5kfGmxbjDBd5NigQ>? M3zOW|QxOMLizsznM41t NUTmWFZIOjRiaB?= NHThTm5{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDjZZNx[XOnLUOsPEw6KGGldHn2bZR6yqB? MnzNNlI1Pjl7NUK=
NT2 MX3GeY5kfGmxbjDBd5NigQ>? NEm4VoI1ODEEoN88[{9udA>? MnO5NlQhcA>? MX\zbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCEQWigcIV3\Wx? NX7HUm9EOjJ2Nkm5OVI>
NT2 MXzGeY5kfGmxbjDBd5NigQ>? MV[0NFDDqM7:Zz;tcC=> NVf6cZVyOjRiaB?= MVLzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyCEY3ytNkBt\X[nbB?= NG\uWXEzOjR4OUm1Ni=>
CHO MlHSSpVv[3Srb36gRZN{[Xl? M1vtWFIvPcLizsznM41t NHi4[mcyQCCqL{[g[C=> MnHIbY5lfWOnc9MgdIVze2m|dHXuZ4Uhd2ZiY3jyc41we2:vZTDkZY1i\2V? NXzxNFJDOjJ{M{CxPVU>
Jurkat NWjQVVA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoToNE0yODEEoN88[{9udA>? NUKwblJVOjRiaB?= NIHPbFdienKnc4TzJJRp\SClZXzsJIN6[2ynIHH0JJRp\SCJMjDwbIF{\Q>? NY\qOW84OjJ{MkOzN|I>
Jurkat NHnH[ZpHfW6ldHnvckBCe3OjeR?= MWWzNOKh|rypL33s Mle1NlQhcA>? NGeyO3VqdmO{ZXHz[ZMhfGinIIDyc5RmcW5ibHX2[Yx{KG:oIHP5Z4xqdnNiREOsJGEh[W6mIFKx M2j5eFIzOjJ|M{Oy
Jurkat NVTBN2I2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rGNFAuOTBywrFOwIcwdWx? M1\hc|I1KGh? M1LCd4lvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkB4cXSqIHHuJGlEPTBidnHseYUhd2ZiMUCw{txoN22O MX6yNlIzOzN|Mh?=
Jurkat NVzYOJZxTnWwY4Tpc44hSXO|YYm= M{e2TVMxyqEQvHevcYw> MkW2NlQhcA>? MkjsbY5kemWjc3XzJJRp\SCnZn\lZ5Qhd2ZicInjcollcW:wZTDvckBxcG:|cHjvdplt[XSrb36gcIV3\Wy|IH;mJIhqe3SxbnWgTFJCNlh? M4j0b|IzOjJ|M{Oy
U2OS EGFPnls MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Lz[|AuOsLizsznM41t NVnRbGw2OjRiaB?= NX3S[pJycW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? M4\yVlIyQDFzMEC3
U2OS KuEnls MoC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLMbmcxNTMEoN88[{9udA>? MmWwNlQhcA>? M3\SXYlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> M{PHOlIyQDFzMEC3
MCF-7 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\nVVAuPDByIN88US=> MYK3NkBp M4\PemxEPTB;MUWxMljDqM7:TR?= MoS0NlE4ODN{OUG=
MCF-7/Adr  NH3uVpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVKwMVQxOCEQvF2= NWHyc2RVPzJiaB?= NWjp[VZlVEN3ME21PE42yqEQvF5CpC=> NUHrOG9QOjF5MEOyPVE>
WI-38 NHvrW5RHfW6ldHnvckBCe3OjeR?= MXqwM|QxNzhy4pEJ{txoN22uwrC= M3fiS|MhcA>? MnfGbY5lfWOnczDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCPTjDmdoVyfWWwY4pCpC=> MlTENlE2QTl4MUK=
hBMSC MVPGeY5kfGmxbjDBd5NigQ>? NGTmRVQxNzRyL{iw5qCK|rypL33sxsA> M4XhbVMhcA>? M2LqO4lv\HWlZYOgZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGViTV6g[pJmeXWnbnP5xsA> MYqyNVU6QTZzMh?=
NCI-H23 M{naVGZ2dmO2aX;uJGF{e2G7 NFf1SIoxNzRyL{iw5qCK|rypL33sxsA> MkHzN{Bp MoHDbY5lfWOnczDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCPTjDmdoVyfWWwY4pCpC=> MXiyNVU6QTZzMh?=
A-549 M{T6Z2Z2dmO2aX;uJGF{e2G7 NFTqVnAxNzRyL{iw5qCK|rypL33sxsA> NHnyZXE{KGh? MWjpcoR2[2W|IHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKE2QIH\y[ZF2\W6ledMg M4SwNVIyPTl7NkGy
PBL  NGPtc|JHfW6ldHnvckBCe3OjeR?= M37y[FAwPDBxOEFihKnPxGdxbX|CpC=> NHrYXmQ{KGh? NXTWclNOcW6mdXPld{BiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JIlv[3KnYYPlJIlvKHSqZTDNUkBnemWzdXXuZ5nDqA>? MV2yNVU6QTZzMh?=
pol β −/− MoX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX[wMlI2NTJyMNMg{txoN22u MYWyOOKhcA>? NVnjNmJ2\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJdqfGhiaX7jdoVie2mwZzDjc45k\W62cnH0bY9ve8Li MXqyNVI2OTl2NB?=
pol β +/+ MoXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVqwMlI2NTJyMNMg{txoN22u NIfJOWczPMLiaB?= MVHk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlid3n0bEBqdmO{ZXHzbY5oKGOxbnPlcpRz[XSrb37zxsA> MUiyNVI2OTl2NB?=
pol β −/− NWThSnNJTnWwY4Tpc44hSXO|YYm= MlnLNE0zNjVizsznM41t MVqyJIg> NIe1WVdk[XW|ZYOgSG5CKGSjbXHn[S=> MYGyNVI2OTl2NB?=
pol β +/+ NFHUWohHfW6ldHnvckBCe3OjeR?= M3zkfFAuOi53IN88[{9udA>? NFWwbVgzKGh? MXnjZZV{\XNiRF7BJIRidWGpZR?= M1\Lc|IyOjVzOUS0
pol β −/− M1v0PGZ2dmO2aX;uJGF{e2G7 NYfOcI1wOC13IN88[{9udA>? NEPPWVM1QCCq M3jMd4NifXOnczDtbYNzd263Y3zleZMh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> MYCyNVI2OTl2NB?=
pol β +/+ NIfHOYJHfW6ldHnvckBCe3OjeR?= MXGwMVUh|rypL33s MXK0PEBp MoflZ4F2e2W|IH3pZ5JwdnWlbHX1d{Bld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5 NWHtVHh5OjF{NUG5OFQ>
TK6  MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TvUVI2NTF3MDFOwIcwdWx? NGjaTYk6PiCq MnjubY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> Mlz3NlExQDF2OEe=
TK6  sLUC+Apn1 NVn0WpE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVraSGF6OjVvMUWwJO69\y:vbB?= MYW5OkBp M{TVWolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NXS5cWdrOjFyOEG0PFc>
TK6 sAPE1+Apn1 M4\FRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XyR|I2NTF3MDFOwIcwdWx? MlHmPVYhcA>? NFHmTpF{cWewaX\pZ4FvfGy7IHnubIljcXS|IHPlcIwh\3Kxd4ToJIRwe2ViZHXw[Y5l\W62bIm= NG\yS4EzOTB6MUS4Oy=>
HCT116 MnfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M333TFI2NTF3MDFOwIcwdWx? MlnDPVYhcA>? MmrDbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NVO0V40{OjFyOEG0PFc>
HCT116 sLUC+Apn1 NXriUWVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTENlUuOTVyIN88[{9udA>? MormPVYhcA>? M1LZNIlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NVfoOoszOjFyOEG0PFc>
HCT116 sAPE1+Apn1 M3H2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYKyOU0yPTBizsznM41t NUj6TGV3QTZiaB?= NXn1fpRWe2mpbnnmbYNidnSueTDpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MUKyNVA5OTR6Nx?=

... Click to View More Cell Line Experimental Data

In vivo Day 7 post-Bleomycin sulfate, CD45+ cells in BALf in NOX-/- is 1.7-fold > WT, 57% of which are Mf that decreases by 67% in WT and 83% in NOX-/- by Day 21. [5]

Protocol

Cell Research:

[4]

+ Expand
  • Cell lines: ADIPO-P2 cells
  • Concentrations: 2.5 μg/mL
  • Incubation Time: 30 minutes
  • Method:

    ADIPO-P2 cells are grown in D-MEM high glucose medium supplemented with 20% fetal calf serum, penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37 °C and 5% CO2 atmosphere. Cells are cultured as monolayer in TC25 Corning flasks containing 1.5 × 105 cells/mL. For each experiment, two flasks are set up, one for the control and one for the treated culture. During the log phase of growth ADIPO-P2 cells are treated with a 30 minutes pulse of 2.5 μg/mL of Bleomycin sulfate. Control cultures are set up in parallel but not exposed to Bleomycin sulfate. Time of exposure and concentration of Bleomycin sulfate are chosen according to previous studies carried out in our laboratory with mammalian cells exposed to Bleomycin sulfate. At the end of the pulse treatment with Bleomycin sulfate, the cells are washed twice with Hank's balanced salt solution and kept in culture with fresh culture medium until harvesting. Cells are continuously maintained in culture during 5 passages or subcultures after treatment. Subcultivation is carried out whenever the cultures became confluent (approximately 4 × 105 cells/mL of culture medium). To estimate cell growth, at the time of subcultivation cells are collected by trypsinization, an aliquot of about 200 μL stained with 0.4% trypan blue, and the number of viable cells is determined. Cells are then suspended in fresh culture medium and dispensed into new culture flasks containing 1 × 105 cells/mL to continue growing. The rest of the cells is discarded or dispensed in another flask for cytogenetic analysis, which is performed at 18 hours and 10 days after the end of treatments. To analyze chromosomal aberrations, colchicine (0.1 μg/mL) is added to cell cultures during the last 3 hours of culture. Chromosome preparations are made following standard procedures. After harvesting, cells are hypotonically shocked, fixed in methanol:acetic acid (3:1), spread onto glass slides and processed for PNA-FISH. Two independent experiments are carried out.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: CD-1 mice
  • Formulation: Saline
  • Dosages: 5 mg/kg, 2 ml/kg
  • Administration: Administered via i.t.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL warmed (66.11 mM)
Water 100 mg/mL (66.11 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 1512.62
Formula

C55H85N17O25S4

CAS No. 9041-93-4
Storage powder
Synonyms NSC125066

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02166463 Recruiting Classical Hodgkin Lymphoma|Stage IIB Hodgkin Lymphoma|Stage IIIB Hodgkin Lymphoma|Stage IVA Hodgkin Lymphoma|Stage IVB Hodgkin Lymphoma National Cancer Institute (NCI) March 2015 Phase 3
NCT02582697 Recruiting Germ Cell Tumor University of Sydney|Australian and New Zealand Urogenital and Prostate Cancer Trials Group|Cambridge University Hospitals NHS Foundation Trust|Cancer Trials Ireland|Childrens Oncology Group|Dana-Farber Cancer Institute|University of Southern California February 2014 Phase 3
NCT01390584 Recruiting Lymphoma Eastern Cooperative Oncology Group|National Cancer Institute (NCI) April 2012 Phase 2
NCT01132807 Active, not recruiting Lymphoma Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) May 2010 Phase 2
NCT01042522 Recruiting Ovarian Granulosa Cell Tumor|Ovarian Gynandroblastoma|Ovarian Sertoli-Leydig Cell Tumor|Ovarian Sex Cord Tumor With Annular Tubules|Ovarian Sex Cord-Stromal Tumor|Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types|Ovarian Steroid Cell Tumor Gynecologic Oncology Group|National Cancer Institute (NCI) February 2010 Phase 2
NCT01026220 Active, not recruiting Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma Childrens Oncology Group|National Cancer Institute (NCI) December 2009 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    what is the ratio between bleomycin A2 and bleomycin B2 in your product?

  • Answer:

    The content of Bleomycin A2 and Bleomycin B2 is 62% and 29% respectively.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Bleomycin Sulfate | Bleomycin Sulfate ic50 | Bleomycin Sulfate price | Bleomycin Sulfate cost | Bleomycin Sulfate solubility dmso | Bleomycin Sulfate purchase | Bleomycin Sulfate manufacturer | Bleomycin Sulfate research buy | Bleomycin Sulfate order | Bleomycin Sulfate mouse | Bleomycin Sulfate chemical structure | Bleomycin Sulfate mw | Bleomycin Sulfate molecular weight | Bleomycin Sulfate datasheet | Bleomycin Sulfate supplier | Bleomycin Sulfate in vitro | Bleomycin Sulfate cell line | Bleomycin Sulfate concentration | Bleomycin Sulfate nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID